BACKGROUND: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an arrhythmogenic disease for which electrophysiological studies (EPS) have shown to be of limited value. OBJECTIVE: This study presents a CPVT family in which marked postpacing repolarization abnormalities during EPS were the only consistent phenotypic manifestation of ryanodine receptor (RyR2) mutation carriers. METHODS: The study was prompted by the observation of transient marked QT prolongation preceding initiation of ventricular fibrillation during atrial fibrillation in a boy with a family history of sudden cardiac death (SCD). Family members underwent exercise and pharmacologic electrocardiographic testing with epinephrine, adenosine, and flecainide. Noninvasive clinical test results were normal in 10 patients evaluated, except for both epinephrine- and exercise-induced ventricular arrhythmias in 1. EPS included bursts of ventricular pacing and programmed ventricular extrastimulation reproducing short-long sequences. Genetic screening involved direct sequencing of genes involved in long QT syndrome as well as RyR2. RESULTS: Six patients demonstrated a marked increase in QT interval only in the first beat after cessation of ventricular pacing and/or extrastimulation. All 6 patients were found to have a heterozygous missense mutation (M4109R) in RyR2. Two of them, presenting with aborted SCD, also had a second missense mutation (I406T- RyR2). Four family members without RyR2 mutations did not display prominent postpacing QT changes. CONCLUSION: M4109R- RyR2 is associated with a high incidence of SCD. The contribution of I406T to the clinical phenotype is unclear. In contrast to exercise testing, marked postpacing repolarization changes in a single beat accurately predicted carriers of M4109R- RyR2 in this family.
BACKGROUND: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an arrhythmogenic disease for which electrophysiological studies (EPS) have shown to be of limited value. OBJECTIVE: This study presents a CPVT family in which marked postpacing repolarization abnormalities during EPS were the only consistent phenotypic manifestation of ryanodine receptor (RyR2) mutation carriers. METHODS: The study was prompted by the observation of transient marked QT prolongation preceding initiation of ventricular fibrillation during atrial fibrillation in a boy with a family history of sudden cardiac death (SCD). Family members underwent exercise and pharmacologic electrocardiographic testing with epinephrine, adenosine, and flecainide. Noninvasive clinical test results were normal in 10 patients evaluated, except for both epinephrine- and exercise-induced ventricular arrhythmias in 1. EPS included bursts of ventricular pacing and programmed ventricular extrastimulation reproducing short-long sequences. Genetic screening involved direct sequencing of genes involved in long QT syndrome as well as RyR2. RESULTS: Six patients demonstrated a marked increase in QT interval only in the first beat after cessation of ventricular pacing and/or extrastimulation. All 6 patients were found to have a heterozygous missense mutation (M4109R) in RyR2. Two of them, presenting with aborted SCD, also had a second missense mutation (I406T- RyR2). Four family members without RyR2 mutations did not display prominent postpacing QT changes. CONCLUSION: M4109R- RyR2 is associated with a high incidence of SCD. The contribution of I406T to the clinical phenotype is unclear. In contrast to exercise testing, marked postpacing repolarization changes in a single beat accurately predicted carriers of M4109R- RyR2 in this family.
Authors: N Sumitomo; K Harada; M Nagashima; T Yasuda; Y Nakamura; Y Aragaki; A Saito; K Kurosaki; K Jouo; M Koujiro; S Konishi; S Matsuoka; T Oono; S Hayakawa; M Miura; H Ushinohama; T Shibata; I Niimura Journal: Heart Date: 2003-01 Impact factor: 5.994
Authors: P J Laitinen; K M Brown; K Piippo; H Swan; J M Devaney; B Brahmbhatt; E A Donarum; M Marino; N Tiso; M Viitasalo; L Toivonen; D A Stephan; K Kontula Journal: Circulation Date: 2001-01-30 Impact factor: 29.690
Authors: S Viskin; K Heller; H V Barron; I Kitzis; M Hamdan; J E Olgin; M J Wong; S E Grant; M D Lesh Journal: J Am Coll Cardiol Date: 1996-12 Impact factor: 24.094
Authors: W Shimizu; C Antzelevitch; K Suyama; T Kurita; A Taguchi; N Aihara; H Takaki; K Sunagawa; S Kamakura Journal: J Cardiovasc Electrophysiol Date: 2000-12
Authors: Alex V Postma; Isabelle Denjoy; Theo M Hoorntje; Jean-Marc Lupoglazoff; Antoine Da Costa; Pascale Sebillon; Marcel M A M Mannens; Arthur A M Wilde; Pascale Guicheney Journal: Circ Res Date: 2002-10-18 Impact factor: 17.367
Authors: Argelia Medeiros-Domingo; Zahurul A Bhuiyan; David J Tester; Nynke Hofman; Hennie Bikker; J Peter van Tintelen; Marcel M A M Mannens; Arthur A M Wilde; Michael J Ackerman Journal: J Am Coll Cardiol Date: 2009-11-24 Impact factor: 24.094
Authors: Silvia G Priori; Carlo Napolitano; Mirella Memmi; Barbara Colombi; Fabrizio Drago; Maurizio Gasparini; Luciano DeSimone; Fernando Coltorti; Raffaella Bloise; Roberto Keegan; Fernando E S Cruz Filho; Gabriele Vignati; Abraham Benatar; Angelica DeLogu Journal: Circulation Date: 2002-07-02 Impact factor: 29.690
Authors: Sonia Franciosi; Thomas M Roston; Frances K G Perry; Bjorn C Knollmann; Prince J Kannankeril; Shubhayan Sanatani Journal: J Cardiovasc Electrophysiol Date: 2019-07-11
Authors: Jian Shan; Wenjun Xie; Matthew Betzenhauser; Steven Reiken; Bi-Xing Chen; Anetta Wronska; Andrew R Marks Journal: Circ Res Date: 2012-07-24 Impact factor: 17.367
Authors: Michael Arad; Michael Glikson; Dalia El-Ani; Lorenzo Monserrat-Inglesias Journal: Ann Noninvasive Electrocardiol Date: 2012-10 Impact factor: 1.468
Authors: Shiraz Haron-Khun; David Weisbrod; Hanna Bueno; Dor Yadin; Joachim Behar; Asher Peretz; Ofer Binah; Edith Hochhauser; Michael Eldar; Yael Yaniv; Michael Arad; Bernard Attali Journal: EMBO Mol Med Date: 2017-04 Impact factor: 12.137